Overcoming mTOR resistance mutations with a new-generation mTOR inhibitorVanessa Rodrik-Outmezguine, Kevan M. Shokat, Masanori Okaniwa et al.|Nature|2016Cited by 483
First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast CancerFrançois‐Clément Bidard, Nicholas C. Turner, Hiroji Iwata et al.|New England Journal of Medicine|2025Cited by 106
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Rachel Schiff, Chad J. Creighton et al.|Breast Cancer Research|2014Cited by 70
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistanceGladys Morrison, Rachel Schiff, Xiaoyong Fu et al.|Breast Cancer Research and Treatment|2014Cited by 61